Wedbush cut shares of Alto Neuroscience (NYSE:ANRO – Free Report) from an outperform rating to a neutral rating in a report released on Wednesday morning, Marketbeat Ratings reports. They currently have $4.00 target price on the stock, down from their previous target price of $29.00.
Other equities research analysts also recently issued research reports about the company. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Robert W. Baird lowered their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday. Finally, Rodman & Renshaw lowered shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $24.40.
Get Our Latest Stock Report on ANRO
Alto Neuroscience Stock Performance
Alto Neuroscience (NYSE:ANRO – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. As a group, research analysts predict that Alto Neuroscience will post -2.63 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Alto Neuroscience
A number of large investors have recently bought and sold shares of ANRO. Federated Hermes Inc. raised its position in Alto Neuroscience by 33.3% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $128,000 after buying an additional 3,000 shares during the last quarter. Bowie Capital Management LLC purchased a new stake in shares of Alto Neuroscience in the 2nd quarter valued at $462,000. TD Asset Management Inc acquired a new stake in shares of Alto Neuroscience in the second quarter worth $928,000. Rhumbline Advisers purchased a new position in shares of Alto Neuroscience during the second quarter worth $113,000. Finally, Bank of New York Mellon Corp acquired a new position in Alto Neuroscience during the second quarter valued at $252,000.
About Alto Neuroscience
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Read More
- Five stocks we like better than Alto Neuroscience
- How to Calculate Inflation Rate
- Texas Roadhouse Stock Steering for New Highs This Year
- What is the NASDAQ Stock Exchange?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- With Risk Tolerance, One Size Does Not Fit All
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.